Loading clinical trials...
Loading clinical trials...
A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Sequential Dose-Escalation Study of TB-500 (Thymosin Beta 4 17-23 Fragment) in Adults With Stable Atherosclerotic Cardiovascular Disease to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Cardiovascular Biomarkers
Conditions
Interventions
TB-500
Placebo
Locations
1
China
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
Start Date
February 5, 2026
Primary Completion Date
February 14, 2027
Completion Date
February 17, 2028
Last Updated
March 23, 2026
NCT07460960
NCT07324902
NCT05000515
NCT04087655
NCT07227740
NCT05808686
Lead Sponsor
Hudson Biotech
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions